Stoke Therapeutics, Inc. (STOK)
Stock Price:
$23.40 USD
0.35 (1.52%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
771.57M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-37.62M |
| Shares Out |
32.97M |
| EPS (ttm) |
-2.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$23.40 |
| Previous Close |
$23.05 |
| Change ($) |
0.35 |
| Change (%) |
1.52% |
| Day's Open |
23.09 |
| Day's Range |
22.94 - 23.77 |
| Day's Volume |
90,789 |
| 52-Week Range |
15.82 - 39.04 |
More Stats
| Market Cap |
771.57M |
| Enterprise Value |
560.07M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.97M |
| Float |
8.11M |
| EPS (basic) |
-2.23 |
| EPS (diluted) |
-2.66 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.13M |
| Short Ratio |
28.39 |
| Short % of Float |
25.87% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.55 |
| Revenue |
n/a |
| Operating Income |
-41.09M |
| Net Income |
-37.62M |
| Free Cash Flow |
n/a |
| Net Cash |
211.49M |
| Net Cash / Share |
6.41 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-15.86% |
| ROE |
-23.97% |
| ROIC |
-2,898.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$37.40*
(59.83% upside)
Low
30.0
Current: 23.40
High
46.0
Target: 37.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -35.68 | -12.78 | -5.55 |
| Net Income | -32.33 | -12.52 | -5.56 |
| Shares Outstanding | 17.97 | 0.71 | 0.67 |
| Earnings Per Share | -1.80 | -17.65 | -8.29 |
| Operating Cash Flow | -31.06 | -10.96 | -5.56 |
| Capital Expenditures | -1.63 | -0.93 | -0.11 |
| Free Cash Flow | -32.69 | -11.89 | -5.67 |
| Cash & Equivalents | 223 | 106 | 1.85 |
| Net Cash / Debt | 223 | 106 | 1.85 |
| Assets | 229 | 108 | 2.44 |
| Liabilities | 4.32 | 2.47 | 3.73 |
| Book Value | 224 | 105 | -1.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Stoke Therapeutics, Inc. |
| Country |
United States |
| Employees |
56 |
| CEO |
Edward M. Kaye |
Stock Information
| Ticker Symbol |
STOK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: STOK |
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.